Drug Resistance in Toxoplasma gondii
Open accessThe DOI matches its Crossref record.
Abstract
Toxoplasma gondii (T. gondii) is a global protozoan parasite infecting up to one-third of the world population. The most widely used drugs for treatment of toxoplasmosis are pyrimethamine (PYR) and sulfadiazine (SDZ); however, several failure cases have been recorded as well; suggesting the existence of drug resistant strains. In this systematic review, the data was collected from six English data bases (PubMed, Science Direct, Scopus, Google Scholar, ISI Web of Science and EBSCO) to evaluate drug resistance in T. gondii including in vitro and in vivo studies. Results of the present review were 34 research papers evaluated 37 drugs and compounds and more than 100 resistant strains of T. gondii during 1977- February 2017. In 12 surveys, T. gondii mutants were identified as a good model to study mechanisms of resistance and drug target in parasites. Interestingly, analogous amino acid substitutions in the Toxoplasma enzyme identified to confer PYR resistance. Moreover, resistance to clindamycin, spiramycin and azithromycin is encoded in the rRNA genes of T. gondii. However, T. gondii SDZ resistance mechanism has not been proved yet. As the only worrying trend is a very slight recent increase in the SDZ resistance, most of the studies were carried out using SDZ. Six resistance strains to SDZ were found in clinical cases between 2013 and 2017. Among them the Brazilian T. gondii isolates, of TgCTBr11, Ck3 and Pg1 were identified in human toxoplasmosis, as well as in livestock intended for human consumption. In conclusion, recent experimental studies in clinical cases have clearly shown that drug resistance in Toxoplasma is ongoing. Thus, establish a more effective therapeutic scheme in the treatment of toxoplasmosis is critically needed. The emergence of T. gondii strains resistant to cur¬rent drugs, reviewed here, repre¬sents a concern not only for treatment failure but also for increased clinical severity in immunocompromised patients. To improve the therapeutic outcome in patients, development of a greater understanding of exact mechanisms of drug resistance in T. gondii is needed. Additionally, monitoring the presence of resistant parasites, in food products, would thus seem a prudent public health program.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 80
- Alday, 2017, Drugs in development for toxoplasmosis: advances, challenges, and current status, Drug Des. Dev. Ther., 11, 273, 10.2147/DDDT.S60973 · DOI · Paper page
- Alves, 2005, Efficacy of atovaquone and sulfadiazine in the treatment of mice infected with Toxoplasma gondii strains isolated in Brazil, Parasite, 12, 171, 10.1051/parasite/2005122171 · doi:10.1051/parasite/2005122171
- Aspinall, 2002, The molecular basis of sulfonamide resistance in Toxoplasma gondii and implications for the clinical management of toxoplasmosis, J. Infect. Dis., 185, 1637, 10.1086/340577 · DOI
- Berens, 1998, Selection and characterization of Toxoplasma gondii mutants resistant to artemisinin, J. Infect. Dis., 177, 1128, 10.1086/517411 · doi:10.1086/517411
- Bossi, 1998, Epidemiologic characteristics of cerebral toxoplasmosis in 399 HIV-infected patients followed between 1983 and 1994, Rev. Med. Interne, 19, 313, 10.1016/S0248-8663(98)80100-8 · doi:10.1016/s0248-8663(98)80100-8
- Capper, 2015, Antimalarial 4 (1H)-pyridones bind to the Qi site of cytochrome bc1, Proc. Natl. Acad. Sci. U. S. A., 112, 755, 10.1073/pnas.1416611112 · DOI
- Chirgwin, 2002, Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 study, Clin. Infect. Dis., 34, 1243, 10.1086/339551 · doi:10.1086/339551
- Crofts, 2004, The cytochrome bc1 complex: function in the context of structure, Annu. Rev. Physiol, 66, 689, 10.1146/annurev.physiol.66.032102.150251 · DOI · Paper page
- Cui, 2015, Antimalarial drug resistance: literature review and activities and findings of the ICEMR network, Am. J. Trop. Med. Hyg., 93, 57, 10.4269/ajtmh.15-0007 · DOI · Paper page
- Daryani, 2018, The potential use of melatonin to treat protozoan parasitic infections: a review, Biomed. Pharmacother., 97, 948, 10.1016/j.biopha.2017.11.007 · doi:10.1016/j.biopha.2017.11.007
- Doggett, 2012, Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis, Proc. Natl. Acad. Sci. U. S. A., 109, 15936, 10.1073/pnas.1208069109 · DOI · Paper page
- Doliwa, Sulfadiazine resistance in Toxoplasma gondii: no involvement of overexpression or polymorphisms in genes of therapeutic targets and ABC transporters, Parasite, 20, 19, 10.1051/parasite/2013020 · DOI
- Doliwa, Induction of sulfadiazine resistance in vitro in Toxoplasma gondii, Exp. Parasitol, 133, 131, 10.1016/j.exppara.2012.11.019 · DOI
- Doliwa, Identification of differentially expressed proteins in sulfadiazine resistant and sensitive strains of Toxoplasma gondii using difference-gel electrophoresis (DIGE), Int. J. Parasitol. Drugs Drug Resist., 3, 35, 10.1016/j.ijpddr.2012.12.002 · doi:10.1016/j.ijpddr.2012.12.002
- Donald, 1993, Stable molecular transformation of Toxoplasma gondii: a selectable dihydrofolate reductase-thymidylate synthase marker based on drug-resistance mutations in malaria, Proc. Natl. Acad. Sci. U. S. A, 90, 11703, 10.1073/pnas.90.24.11703 · doi:10.1073/pnas.90.24.11703
- Fox, 1999, Stable transformation of Toxoplasma gondii based on a pyrimethamine resistant trifunctional dihydrofolate reductase-cytosine deaminase-thymidylate synthase gene that confers sensitivity to 5-fluorocytosine, Mol. Biochem. Parasitol, 98, 93, 10.1016/S0166-6851(98)00154-6 · doi:10.1016/s0166-6851(98)00154-6
- Gajurel, 2016, Failure of primary atovaquone prophylaxis for prevention of toxoplasmosis in hematopoietic cell transplant recipients, Transpl. Infect. Dis., 18, 446, 10.1111/tid.12532 · doi:10.1111/tid.12532
- Garrison, 2009, Disruption of a mitochondrial MutS DNA repair enzyme homologue confers drug resistance in the parasite Toxoplasma gondii, Mol. Microbiol, 72, 425, 10.1111/j.1365-2958.2009.06655.x · doi:10.1111/j.1365-2958.2009.06655.x
- Glasner, 1992, An unusually high prevalence of ocular toxoplasmosis in southern Brazil, Am. J. Ophthalmol., 114, 136, 10.1016/S0002-9394(14)73976-5 · DOI · Paper page
- Hegewald, 2013, Identification of dihydroorotate dehydrogenase as a relevant drug target for 1-Hydroxyquinolones in Toxoplasma gondii, Mol. Biochem. Parasitol, 190, 6, 10.1016/j.molbiopara.2013.05.008 · doi:10.1016/j.molbiopara.2013.05.008
- Howe, 1995, Toxoplasma gondii comprises three clonal lineages: correlation of parasite genotype with human disease, J. Infect. Dis, 172, 1561, 10.1093/infdis/172.6.1561 · DOI · Paper page
- Jacobson, 1996, Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii, Antimicrob. Agents Chemother., 40, 1360, 10.1128/AAC.40.6.1360 · doi:10.1128/aac.40.6.1360
- Kessl, 2006, Molecular basis of Toxoplasma gondii atovaquone resistance modeled in Saccharomyces cerevisiae, Mol. Biochem. Parasitol, 146, 255, 10.1016/j.molbiopara.2005.12.002 · DOI
- Kovacs, 1992, Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS, Lancet, 340, 637, 10.1016/0140-6736(92)92172-C · DOI
- Kropf, 2012, The adaptive potential of a survival artist: characterization of the in vitro interactions of Toxoplasma gondii tachyzoites with di-cationic compounds in human fibroblast cell cultures, Parasitology, 139, 208, 10.1017/S0031182011001776 · doi:10.1017/s0031182011001776
- Lavine, 2012, Analysis of monensin sensitivity in Toxoplasma gondii reveals autophagy as a mechanism for drug induced death, PLoS ONE, 7, e42107, 10.1371/journal.pone.0042107 · DOI
- Lawres, 2016, Radical cure of experimental babesiosis in immunodeficient mice using a combination of an endochin-like quinolone and atovaquone, J. Exp. Med., 27, 1307, 10.1084/jem.20151519 · DOI
- Lindsay, 1995, Ultrastructural effects of diclazuril against Toxoplasma gondii and investigation of a diclazuril-resistant mutant, J. Parasitol, 81, 459, 10.2307/3283832 · doi:10.2307/3283832
- Luft, 1992, Toxoplasmic encephalitis in AIDS, Clin. Infect. Dis, 15, 211, 10.1093/clinids/15.2.211 · DOI · Paper page
- Ma, 2007, Mutations in α-tubulin confer dinitroaniline resistance at a cost to microtubule function, Mol. Biol. Cell, 18, 4711, 10.1091/mbc.e07-04-0379 · DOI
- Ma, 2008, Secondary mutations correct fitness defects in Toxoplasma gondii with dinitroaniline resistance mutations, Genetics, 180, 845, 10.1534/genetics.108.092494 · doi:10.1534/genetics.108.092494
- McFadden, 2001, Resistance as a tool in the study of old and new drug targets in Toxoplasma, Drug Resist. Updates, 4, 79, 10.1054/drup.2001.0184 · DOI
- McFadden, 1997, Use of Toxoplasma gondii expressing -galactosidase for colorimetric assessment of drug activity in vitro, Antimicrob. Agents Chemother., 41, 1849, 10.1128/AAC.41.9.1849 · doi:10.1128/aac.41.9.1849
- McFadden, 2000, Characterization of cytochrome b from Toxoplasma gondii and Q o domain mutations as a mechanism of atovaquone-resistance, Mol. Biochem. Parasitol, 108, 1, 10.1016/S0166-6851(00)00184-5 · DOI · Paper page
- McLeod, 2006, Outcome of treatment for congenital toxoplasmosis, 1981–2004: the national collaborative Chicago-based, congenital toxoplasmosis study, Clin. Infect. Dis, 42, 1383, 10.1086/501360 · DOI · Paper page
- Meneceur, 2008, In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone, Antimicrob. Agents.Chemother., 52, 1269, 10.1128/AAC.01203-07 · DOI
- Moncada, 2012, Toxoplasmosis in the fetus and newborn: an update on prevalence, diagnosis and treatment, Expert Rev. Anti Infect. Ther, 10, 815, 10.1586/eri.12.58 · DOI · Paper page
- Montazeri, 2015, Effect of propranolol alone and in combination with pyrimethamine on acute murine toxoplasmosis, Jundishapur J.Microbiol, 8, e22572, 10.5812/jjm.22572 · doi:10.5812/jjm.22572
- Montazeri, 2018, Activities of anti-Toxoplasma drugs and compounds against tissue cysts in the last three decades (1987 to 2017), a systematic review, Parasitol. Res, 117, 3045, 10.1007/s00436-018-6027-z · DOI
- Montazeri, Survey on synergism effect of ketotifen in combination with pyrimethamine in treatment of acute murine toxoplasmosis, Trop. Med. Int, 45, 39, 10.1186/s41182-017-0079-0 · doi:10.1186/s41182-017-0079-0
- Montazeri, A systematic review of in vitro and in vivo activities of anti-toxoplasma drugs and compounds (2006–2016), Front Microbiol., 8, 25, 10.3389/fmicb.2017.00025 · DOI · Paper page
- Montoya, 2004, Toxoplasmosis, Lancet, 363, 1965, 10.1016/S0140-6736(04)16412-X · DOI · Paper page
- Morrissette, 2004, Dinitroanilines bind α-tubulin to disrupt microtubules, Mol. Biol. Cell, 15, 1960, 10.1091/mbc.e03-07-0530 · DOI
- Nagamune, 2007, Artemisinin-resistant mutants of Toxoplasma gondii have altered calcium homeostasis, Antimicrob. Agents Chemother., 51, 3816, 10.1128/AAC.00582-07 · DOI
- Nair, 2011, Apicoplast isoprenoid precursor synthesis and the molecular basis of fosmidomycin resistance in Toxoplasma gondii, J. Exp. Med, 208, 1547, 10.1084/jem.20110039 · DOI
- Oliveira, 2016, Pathogenicity and phenotypic sulfadiazine resistance of Toxoplasma gondii isolates obtained from livestock in northeastern Brazil, Mem Inst Oswaldo Cruz, 111, 391, 10.1590/0074-02760150459 · doi:10.1590/0074-02760150459
- Ouellette, 2001, Biochemical and molecular mechanisms of drug resistance in parasites, Trop. Med. Int. Health, 6, 874, 10.1046/j.1365-3156.2001.00777.x · DOI
- Oz, 2014, Novel synergistic protective efficacy of atovaquone and diclazuril on fetal-maternal toxoplasmosis, Int. J. Clin. Med, 5, 921, 10.4236/ijcm.2014.515124 · DOI
- Pappas, 2009, Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis, Int. J. Parasitol., 39, 1385, 10.1016/j.ijpara.2009.04.003 · DOI · Paper page
- Pfefferkorn, Comparison of mutants of Toxoplasma gondii selected for resistance to azithromycin, spiramycin, or clindamycin, Antimicrob. Agents Chemother., 38, 31, 10.1128/AAC.38.1.31 · doi:10.1128/aac.38.1.31
- Pfefferkorn, Toxoplasma gondii: characterization of a mutant resistant to 6-thioxanthine, Exp Parasitol, 79, 374, 10.1006/expr.1994.1099 · doi:10.1006/expr.1994.1099
- Pfefferkorn, Toxoplasma gondii: characterization of a mutant resistant to sulfonamides, Exp Parasitol, 74, 261, 10.1016/0014-4894(92)90149-5 · DOI
- Pfefferkorn, 1993, Mutants of Toxoplasma gondii resistant to atovaquone (566C80) or decoquinate, J. Parasitol, 79, 559, 10.2307/3283383 · doi:10.2307/3283383
- Pfefferkorn, 1988, Toxoplasma gondii: in vivo and in vitro studies of a mutant resistant to arprinocid-N-oxide, Exp. Parasitol, 65, 282, 10.1016/0014-4894(88)90133-6 · doi:10.1016/0014-4894(88)90133-6
- Pfefferkorn, 1983, Toxoplasma gondii: genetic crosses reveal phenotypic suppression of hydroxyurea resistance by fluorodeoxyuridine resistance, Exp. Parasitol., 55, 207, 10.1016/0014-4894(83)90015-2 · doi:10.1016/0014-4894(83)90015-2
- Pfefferkorn, Parasiticidal effect of clindamycin on Toxoplasma gondii grown in cultured cells and selection of a drug-resistant mutant, Antimicrob. Agents Chemother., 36, 1091, 10.1128/AAC.36.5.1091 · doi:10.1128/aac.36.5.1091
- Pfefferkorn, 1977, Toxoplasma gondii: characterization of a mutant resistant to 5-fluorodeoxyuridine, Exp. Parasitol, 42, 44, 10.1016/0014-4894(77)90060-1 · doi:10.1016/0014-4894(77)90060-1
- Pfefferkorn, 1978, The biochemical basis for resistance to adenine arabinoside in a mutant of Toxoplasma gondii, J. Parasitol, 64, 486, 10.2307/3279789 · DOI
- Pfefferkorn, 1980, Toxoplasma gondii: genetic recombination between drug resistant mutants, Exp. Parasitol., 50, 305, 10.1016/0014-4894(80)90034-X · doi:10.1016/0014-4894(80)90034-x
- Porter, 1992, Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome, N. Engl. J. Med, 327, 1643, 10.1056/NEJM199212033272306 · DOI · Paper page
- Rajapakse, 2013, Antibiotics for human toxoplasmosis: a systematic review of randomized trials, Pathog. Glob. Health, 107, 162, 10.1179/2047773213Y.0000000094 · DOI
- Reynolds, 2001, In Vitro generation of novel pyrimethamine resistance mutations in the Toxoplasma gondii dihydrofolate reductase, Antimicrob. Agents Chemother., 45, 1271, 10.1128/AAC.45.4.1271-1277.2001 · doi:10.1128/aac.45.4.1271-1277.2001
- Reynolds, 1998, A biochemical and genetic model for parasite resistance to antifolates Toxoplasma gondii provides insights into pyrimethamine and cycloguanil resistance in Plasmodium falciparum, J. Biol. Chem, 273, 3461, 10.1074/jbc.273.6.3461 · DOI
- Ricketts, 1993, Toxoplasma gondii: susceptibility and development of resistance to anticoccidial drugs in vitro, Antimicrob. Agents Chemother., 37, 2358, 10.1128/AAC.37.11.2358 · doi:10.1128/aac.37.11.2358
- Sander, 1971, Development of sulphonamide resistance in Toxoplasma gondii, APMIS, 79, 531
- Schultz, 2014, A thiazole derivative of artemisinin moderately reduces Toxoplasma gondii cyst burden in infected mice, J. Parasitol, 100, 516, 10.1645/13-451.1 · doi:10.1645/13-451.1
- Sepúlveda-Arias, 2014, Toxoplasmosis as a travel risk, Travel Med. Infect. Dis., 12, 592, 10.1016/j.tmaid.2014.05.007 · doi:10.1016/j.tmaid.2014.05.007
- Shwab, 2014, Geographical patterns of Toxoplasma gondii genetic diversity revealed by multilocus PCR- RFLP genotyping, Parasitology, 141, 453, 10.1017/S0031182013001844 · DOI · Paper page
- Silva, 2017, Genetic polymorphisms and phenotypic profiles of sulfadiazine-resistant and sensitive Toxoplasma gondii isolates obtained from newborns with congenital toxoplasmosis in minas gerais, Brazil, PloS ONE, 12, e0170689, 10.1371/journal.pone.0170689 · DOI
- Sims, 2009, Drug resistance in Toxoplasma gondii, 1121, 10.1007/978-1-60327-595-8_31 · DOI
- Sugi, 2010, Use of the kinase inhibitor analog 1NM-PP1 reveals a role for Toxoplasma gondii CDPK1 in the invasion step, Eukaryotic Cell, 9, 667, 10.1128/EC.00351-09 · doi:10.1128/ec.00351-09
- Sugi, 2015, A single mutation in the gatekeeper residue in TgMAPKL-1 restores the inhibitory effect of a bumped kinase inhibitor on the cell cycle, Int. J. Parasitol. Drugs Drug Resist., 5, 1, 10.1016/j.ijpddr.2014.12.001 · DOI
- Sugi, 2013, Identification of mutations in TgMAPK1 of Toxoplasma gondii conferring resistance to 1NM-PP1, Int. J. Parasitol. Drugs Drug Resist, 3, 93, 10.1016/j.ijpddr.2013.04.001 · doi:10.1016/j.ijpddr.2013.04.001
- Tenter, 2000, Toxoplasma gondii: from animals to humans, Int. J. Parasitol., 30, 1217, 10.1016/S0020-7519(00)00124-7 · DOI · Paper page
- Tomavo, 1995, Interconnection between organellar functions, development and drug resistance in the protozoan parasite, Toxoplasma gondii, Int. J. Parasitol., 25, 1293, 10.1016/0020-7519(95)00066-B · DOI
- Vaillant, 2005, Foodborne infections in France, Foodborne Pathog. Dis, 2, 221, 10.1089/fpd.2005.2.221 · DOI · Paper page
- Van Voorhis, 2017, Extended-spectrum antiprotozoal bumped kinase inhibitors: a review, Exp. Parasitol., 180, 71, 10.1016/j.exppara.2017.01.001 · DOI
- Villena, 1998, Pyrimethamine-sulfadoxine treatment of congenital toxoplasmosis: follow-up of 78 cases between 1980 and 1997, Scand. J. Infect. Dis, 30, 295, 10.1080/00365549850160963 · DOI
- Wang, 2017, Toxoplasma gondii infection in immunocompromised patients: a systematic review and meta-analysis, Front. Microbiol., 8, 389, 10.3389/fmicb.2017.00389 · DOI · Paper page
- Winter, 2008, Antimalarial quinolones: synthesis, potency, and mechanistic studies, Exp. Parasitol., 118, 487, 10.1016/j.exppara.2007.10.016 · doi:10.1016/j.exppara.2007.10.016
Cited by
Advances in Toxoplasma gondii vaccines: current strategies and challenges for vaccine development
Chu, K.-B., & Quan, F.-S. (2021) · Vaccines · doi:10.3390/vaccines9050413 · Cited by 92
“gondii which may exacerbate the disease severity and result in treatment failure [2].”
BackgroundLi, D., Zhang, Y., Li, S., & Zheng, B. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1145114 · Cited by 22
Metadata
- Authors
- Montazeri, M., Mehrzadi, S., Sharif, M., Sarvi, S., Tanzifi, A., Aghayan, S. A., & Daryani, A.
- Venue
- Frontiers in Microbiology
- Publisher
- Frontiers Media SA
- Published
- 2018-10-29
- Volume
- 9
- Pages
- 2587-2587
- ISSN
- 1664-302X (ISSN-L)
- OpenAlex
- W2898821708
- Cited by
- 217
- References
- 0
- FWCI
- 12.17
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug Resistance in Toxoplasma gondii. https://app.cochat.ai/papers/10.3389/fmicb.2018.02587
- The paper
- Montazeri, M., Mehrzadi, S., Sharif, M., Sarvi, S., Tanzifi, A., Aghayan, S. A., & Daryani, A. (2018). Drug Resistance in Toxoplasma gondii. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2018.02587
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.